The Cell Fate Determination Factor Dachshund Inhibits Androgen Receptor Signaling and Prostate Cancer Cellular Growth

Kongming Wu,1 Sanjay Katiyar,1 Agnes Witkiewicz,2 Anping Li,1 Peter McCue,2 Liang-Nian Song,3 Lifeng Tian,1 Ming Jin,1 and Richard G. Pestell1

1Department of Cancer Biology, Kimmel Cancer Center and Department of Pathology, Thomas Jefferson University, Bluemle Life Sciences Building, Philadelphia, Pennsylvania; and 2Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York

Abstract

Initially isolated as the dominant suppressor of the mutant epidermal growth factor receptor (ellipse), the Dachshund gene plays a key role in metazoan development regulating the Retinal Determination Gene Network. Herein, the DACH1 gene was expressed in normal prostate epithelial cells with reduced expression in human prostate cancer. DACH1 inhibited prostate cancer cellular DNA synthesis, growth in colony forming assays, and blocked contact-independent growth in soft agar assays. DACH1 inhibited androgen receptor (AR) activity, requiring a conserved DS Domain (Dachshund domain conserved with Ski/Sno) that bound NCoR/HDAC activity, and was recruited to an androgen-responsive gene promoter. DACH1 inhibited ligand-dependent activity of AR mutations identified in patients with androgen-insensitive prostate cancer. The DS domain was sufficient for repression of the AR wild-type but failed to repress an AR acetylation site point mutant. These studies show a role for the Retinal Determination Gene Network in regulating cellular growth and signaling in prostate cancer. [Cancer Res 2009;69(8):3347–55]

Introduction

Prostate cancer is the most frequently diagnosed cancer of men in the United States and the second leading cause of male cancer deaths (1, 2). Hyperactivation of the androgen receptor (AR) is a fundamental driver of prostate cancer progression (3), and AR antagonists are the frontline of therapeutic intervention (4). Increased expression and/or activity of the AR is a common feature during prostate cancer onset and progression. Androgen ablation therapy results in a 60% to 80% initial response rate. Understanding the molecular mechanisms governing the growth property of the AR is essential to devise targeted therapies for prostate cancer, including androgen-insensitive prostate cancer.

The AR is a ligand-activated transcription factor that belongs to the superfamily of steroid receptors (5). These receptors have similar protein structures and are composed of an NH2-terminal domain that contains an activation function (AF-1), a DNA-binding domain, a hinge region, and a ligand binding domain that contains a second activation function domain (AF-2). Upon binding of ligands, such as dihydrotestosterone (DHT), the AR translocates to the nucleus and undergoes a conformational change that results in formation of a homodimer and the recruitment of multiple transcription factors that activate the expression of androgen-dependent genes (5). Activity of the AR is mediated via a balance between the function of coactivators [CBP/p300, Tip-60, and AR activator proteins (ARA); refs. 6, 7] and corepressor proteins [including NCoR, Smads, and histone deacetylases (HDAC, SIRT1; refs. 8–10)]. In contrast with the wild-type (wt) AR, mutant AR that arise in patients with prostate cancer are promiscuously activated by a variety of hormones (estrogen, progesterone) that would normally have no effect on the wt AR (11). These AR ligand binding mutations cause an androgen antagonist such as flutamide to behave as androgen agonist (12).

Upon ligand binding to the AR, posttranslational modifications are induced including phosphorylation, acetylation, and ubiquitination, which in turn determine transcriptional and growth regulatory functions (13). The AR, like several other nuclear receptors, is directly acetylated at a motif that is widely conserved among various species (14–17). AR acetylation, which is induced by agonists including DHT and bombesin (18), governs prostate cancer cellular growth (15). Thus, gain of function mutants of the AR-acetylation site promote growth of human prostate cancer cells in tissue culture and when implanted in nude mice (15). The enhanced cellular growth is mediated by reduced MAPK kinase 1–induced apoptosis (16) and enhanced cellular proliferation through induction of cell-cycle regulatory genes (16).

Conversely, ligand-dependent AR activity is repressed by HDACs of both the TSA-dependent type (class I and II) and by the class III HDAC. Corepressors of the AR, including HDAC1, HDAC3, and NCoR can bind the AR in the context of local chromatin and disengage in the presence of ligand (19–21). The class III HDACs are homologous to the transcriptional repressor Sir2P. It is known that class I and class II HDACs are sensitive to the inhibitor Trichostatin A (TSA). Class III HDAC activity is nicotinamide-adenine dinucleotide-dependent and cannot be inhibited by TSA. SIRT1 represses ligand-dependent AR activity and SIRT1 deacetylates the AR with similar kinetics and Km to that described for p53 (10). Inhibition of class III HDACs activity in prostate cancer cells enhances liganded AR activity and AR expression (10), suggesting an important biological role for endogenous class III HDACs in AR signaling (22). SIRT1 inhibits prostate cancer cellular growth in the presence of the AR (10).

Although AR corepressors inhibit AR function, studies to date have not revealed significant alteration in the abundance of AR corepressor proteins during prostate cancer onset and progression. Recent studies have identified a protein resembling the NCoR/Ski family that physically associates with HDAC1 and HDAC3, known as Dachshund1 (23). DACH1 repression function has been linked to its association with HDAC1, HDAC3, Sin3, and NcoR, which colocalized with DACH1 at the promoters of target genes...
genes repressed by DACH1 (23, 24). The Dachshund1 (DACH1) gene was initially identified in Drosophila as a dominant suppressor of Ellipse, a constitutively active epidermal growth factor receptor (EGFR; ref. 25). The Dac gene is known to play a key role in metazoan development regulating ocular, limb, and gonadal development. In the Drosophila eye, Dac encodes a key component of the Retinal Determination Gene Network. Loss of function mutations of the gene result in defective eye development, whereas ectopic Dac expression is sufficient for the induction of eye development implicating Dac in organizing cellular fate (25).

The DACH1 gene encodes a protein with winged helix-Forkhead subgroup structure of the helix-turn-helix family (26). Although no specific DNA binding characteristics have been identified, DACH1 has been identified in the context of local chromatin by chromatin immunoprecipitation (ChIP) assays within distinct DNA binding sites for the transcription factors Smad, e-Jun, cAMP-responsive element binding protein, and Six1 (23, 24, 27). Thus, the DACH1 gene product uses other DNA-binding transcription factors to regulate gene expression. A conserved domain (Dachshund domain 1) has significant identity with the Ski/Sno (Dachshund DS domain), which is conserved from Drosophila to human. DACH1 gene expression is lost in metastatic human breast cancer (23). The loss of DACH1 expression correlates with poor prognosis. DACH1 inhibited cellular migration and invasion of oncogene (Ras, Myc, ErbB2)-transformed human mammary epithelial cells. Interleukin-8 is a critical target of DACH1-mediated breast cancer cellular migration in vitro and metastasis in vivo (28). In ovarian cancer, DACH1 is overexpressed and may promote tumor progression by antagonizing transforming growth factor β signaling (29, 30).

The role of DACH1 gene expression in prostate cancer was unknown. In the current studies, DACH1 abundance was reduced in human prostate cancer. Re-expression of DACH1 inhibited prostate cancer cellular growth and colony formation in soft agar assays. DACH1 inhibited DHT-dependent AR activity requiring the conserved DS domain. DACH1 inhibited the activity of mutant AR derived from patient samples. The DACH1 gene is a novel inhibitor of prostate cancer cellular growth, inhibiting ligand-dependent AR activity.

Materials and Methods

Plasmid construction, reporter genes, expression vectors, reagents, and kits. The expression plasmids encoding an NH2-terminal FLAG peptide linked to DACH1, DACH1 DS-domain alone (DS) or DACH1 DS-domain deleted (ΔDS), the tet-inducible DACH1 expression vector, and DACH1-VP16 fusion protein were previously described (27, 30). The Ski cDNA was subcloned into the 3× FLAG-CMV7.1 vector (Sigma). Expression vectors for human TIP-60, SRC-1, ARA70, and SIRT1 were previously described (10, 15, 16). The androgen-responsive synthetic reporter constructs [MMTV-LUC, PSA-LUC, Sc-ARE (ARE)2LUC, pG5LUC] and the expression vectors (pCMVHA-p300, pcDNA3AR-GFP, hARwt, the AR carboxyl terminal ligand binding domain 1) has significant identity with the Ski/Sno (Dachshund DS domain 1) has significant identity with the Ski/Sno (Dachshund DS domain) were previously described (10, 11, 15, 17, 31, 32). DHT, R1181, TSA, and Nicotinamide were purchased from Sigma. Free PSA in the culture medium was measured by Free-PSA ELISA kit from BioQuant.

Cell culture, DNA transfection, and luciferase assays. Cell culture, DNA transfection, and luciferase assays were performed as previously described (15–17). The CV1, DU145, LNCaP and HEK293T cell lines were cultured as previously described (10). Transfection and data analyses were as described in Supplementary Data.

DNA synthesis analysis and colony formation assay. DNA synthesis was analyzed by 3H-dTh incorporation. Cells (1 × 10⁶) were plated into 24-well plate and cultured for 36 h. 3H-dTh (1 μCi) was added to each well and culture continued for 2 h. Cells were washed and fixed with incorporation of 3H-dTh measured by liquid scintillation. For contact-dependent growth, 4 × 10⁵ LNCaP cells were plated in triplicate in the presence or absence of 2 μg/ml doxycycline into 6-cm dish and medium was changed every 3 d. The colonies were visualized after 2 wk of growing by staining with 0.04% crystal violet in methanol for 1 h. For contact-independent growth assays, 4 × 10⁵ LNCaP cells were plated in triplicate in 2 mL of 0.3% agarose in complete growth medium in the presence or absence of 2 μg/ml doxycycline overlaid on a 0.5% agarose base, also in complete growth medium. Two weeks after incubation, colonies >500 μm in diameter were counted using an Omnicron 3600 image analysis system.

Western blot analysis, tissue microarrays, and immunohistochemistry. Western blot analysis using antibodies to FLAG, AR (Santa Cruz Biotechnology), and the loading control β-tubulin was conducted as described (10). Immunohistochemistry for DACH1 was performed as previously described (23, 30). A human prostate tissue array consisting of 32 paired prostate cancer tissues with corresponding normal tissues was from AccuMax Array (MD, USA, ISU Abaxis). The immunostaining intensity was scored as negative, 0; minimally positive, 1; positive, 2; strong positive, 3; respectively. The DACH1-positive cells were counted and recorded by a pathologist.

RNA extraction from formalin-fixed paraffin-embedded human prostate tissue specimens, real-time quantitative PCR. RNA was extracted from formalin-fixed paraffin-embedded archival human prostate tissue blocks containing 10 normal human prostates and 10 matched prostate tumor tissue specimen, using RecoverAll Total Nucleic Acid Isolation kit for formalin-fixed paraffin-embedded Tissues (Applied Biosystems). Subsequent analysis was as described in Supplementary Data (28).

ChIP assays. Endogenous PSA promoter ChIP assays using antibodies directed to the FLAG epitope of DACH1, AR, Sirt1, NCoR, HDAC3, and control IgG were performed as previously described (refs. 9, 23, 28, 33; see Supplementary information).

Results

DACH1 expression is reduced in human prostate cancer. To determine the relative abundance of DACH1 in normal and prostate cancer samples, immunohistochemical staining was performed on paired normal and prostate cancer tissues, using a previously well-characterized antibody (23). DACH1 staining was identified in the nucleus and cytoplasm of normal prostate epithelial cells (Fig. 1A). Approximately 35% of epithelial cells stained positively for DACH1 in the normal prostate. The relative intensity of the immunohistochemical staining was quantitated for each sample. Relative mean intensity was compared between those individual samples staining positively for DACH1 in the normal and tumorous tissues. The relative intensity of immunostaining was significantly reduced (~2-fold) in the prostate tumors, compared with the corresponding normal prostate epithelium (Fig. 1B). The percentage of cells staining for DACH1 was also significantly reduced (~7-fold; Fig. 1B). The relative abundance of DACH1 mRNA was assessed in matched prostate tissue comparing normal and prostate cancer samples from each patient (Fig. 1C). The relative abundance was normalized for epithelial cells using KLK3 (PSA) mRNA. DACH1 mRNA was reduced in prostate cancer samples compared with the normal prostate tissue of the individual. Thus, the relative abundance of DACH1 is reduced in prostate cancer epithelium compared with normal prostate epithelium.

DACH1 inhibits human prostate cancer cellular growth. To determine the role of DACH1 in prostate cancer cellular growth,
the LNCaP cell line was used to create tetracycline inducible DACH1 gene expression. The addition of doxycycline induced DACH1 expression as characterized by Western blot analysis to the FLAG epitope of the DACH1 protein (Supplementary Fig. S1A). β-Tubulin, used as a loading control for protein abundance, showed similar protein levels. Doxycycline did not affect ³H thymidine uptake in LNCaP cells. DACH1 expression inhibited LNCaP cell proliferation by >60% (Fig. 2A). Contact-dependent growth of LNCaP cells was characterized by colony formation assay. LNCaP cells formed colonies in tissue culture (Fig. 2B). The number and size of colonies were reduced by >85% upon expression of DACH1. The induction of DACH1 expression upon doxycycline treatment reduced colony formation in soft agar by >85% (Fig. 2C). Dihydrotestosterone (10⁻⁸ M) induced PSA secretion ~9.5-fold (Fig. 2D). Expression of DACH1 reduced DHT-dependent induction of prostate-specific antigen (PSA) by ~60% (Fig. 2D). Collectively, these studies show that DACH1 inhibits LNCaP cell contact–dependent growth and DNA synthesis.

**DACH1 repression of ligand-dependent AR activity involves the DS domain.** As DACH1 expression had inhibited PSA secretion

![Figure 1. Immunohistochemical staining and mRNA expression of DACH1 in human prostate cancer. A, representative example of DACH immunostaining of normal prostate and prostate cancer (×400). B, quantification of DACH1 relative immune intensity and percent of cells staining for DACH1. C, DACH1 mRNA determined by quantitative PCR. Comparison was made between matched normal and tumorous prostate samples.](image)

**Figure 2.** DACH1 inhibits prostate cancer cellular proliferation and growth. A, DNA synthesis analysis of LNCaP DACH1-doxycycline–inducible cell line. Columns, mean for five separate experiments; bars, SE. The doxycycline (Dox)-inducible DACH1 LNCaP cell line was assessed for (B) colony formation, (C) contact-independent growth in soft agar, and (D) PSA secretion in the media determined by ELISA. Columns, mean throughout (n > 5); bars, SE. Veh, vehicle.

![Figure 2](image)
of LNCaP cells, we considered the possibility that DACH1 may directly inhibit AR transcriptional activity. To determine whether DACH1 inhibited AR transcriptional activity, CV1 cells were used and androgen-responsive reporter genes encoding Androgen Response cis Elements (ARE) were cotransduced with an expression vector encoding the wt AR. In the presence of DHT and the AR, ARE activity was induced ~450-fold. The transfection of increasing doses of DACH1 expression vector reduced repression of ligand-dependent AR activity assay using the ARE reporter gene (Fig. 3A). To determine the specificity of transcriptional repression of AR signaling by DACH1, comparison was made with a deletion mutant of the conserved DS domain of DACH1 (DACH1 ΔDS). Transfection of equal amounts of the DACH1 ΔDS-expressing vector failed to repress ligand-dependent activity of the AR (Fig. 3A). Expression of the DS domain alone, however, was sufficient for repression of ligand-dependent AR activity (Fig. 3A). As the DS domain shares identity with the Ski protein at the amino acid level, we examined the effect of Ski expression on ligand-dependent AR activity. In contrast with DACH1, expression of Ski failed to repress ligand-dependent activation of the AR (Fig. 3A). Similar experiments were conducted using the PSA promoter luciferase reporter gene. Addition of the AR agonist R1881 induced PSA luciferase reporter activity ~60-fold (Fig. 3B). Expression of DACH1 reduced PSA-Luc activity ~40-fold. The deletion of the DS domain abrogated DACH1 repression and, as with a simple ARE, Ski failed to repress AR activity assessed using the PSA promoter (Fig. 3B). As the transcriptional repression function of corepressors may vary by cell type, we examined the repression function of DACH1 in the AR-deficient prostate cancer cells DU145. The addition of DHT with the AR induced PSA luciferase activity ~12-fold (Fig. 3C). DHT-induced AR activity was reduced ~8-fold upon expression of DACH1. Deletion of the DS domain abrogated DACH1-dependent repression of ligand-dependent activity of the PSA promoter (Fig. 3C). Similarly, in HEK293T cells, the ligand-dependent activation of the PSA promoter was repressed from 6- to 3-fold by DACH1 expression. The effect of DACH1 was abrogated by deletion of the DS domain and the DS domain alone was sufficient for repression of ligand-dependent AR activity (Supplementary Fig. S1B). We examined the effect of DACH1 in regulating ligand-dependent AR activity at distinct AREs. The secretory component of the polymeric immunoglobulin receptor gene is an androgen-responsive gene responsible for transepithelial transport of IgA and IgM. The scARE was linked to the luciferase reporter gene and transduced into the LNCaP and HEK293T cells. DHT induced scARE activity ~2.5-fold, and this activity was abrogated by expression of DACH1 (Supplementary Fig. S1C; Fig. 3D). Thus, DACH1 inhibits ligand-dependent AR activity requiring the DS domain assessed using multiple distinct AREs in both DU145 and CV-1 cells.

**DACH1 recruits NCoR and SirT1 to endogenous AREs.** The AR associates in the context of local chromatin at AREs within the proximal PSA promoter as assessed by ChIP assays. To determine whether DACH1-mediated AR repression involved direct association of DACH1 at an endogenous ARE, ChIP studies were...
conducted in LNCaP cells. A doxycycline-inducible retrovirus expression vector encoding FLAG-tagged DACH1 was used to transduce LNCaP cells. ChIP analyses were conducted in the presence of vehicle, DHT (10 nmol/L), or the DHT antagonist Casodex (15 μmol/L). Comparison was made between the PSA proximal promoter (ARE I-II), the enhancer (ARE III), and a distal region of the PSA promoter that does not bind the AR as a form of negative control (Fig. 4A). ChIP conducted to DACH1 showed Tet-induced DACH1 expression correlated with DACH1 recruitment to the PSA ARE I-II and ARE III but not the control distal promoter region (Fig. 4B). DHT reduced and Casodex enhanced DACH1 recruitment to ARE I-II/III. In the presence of DHT, the AR abundance was increased at ARE I-II/III, which was reduced by Casodex or DACH1 expression (Fig. 4B). NCoR recruitment was enhanced by DACH1 expression at ARE I-II/III with further recruitment by Casodex at ARE III. NCoR and DACH1 associate with class II TSA-sensitive HDACs. Recent studies showed SirT1 represses the AR through deacetylation and is recruited to the ARE (10, 34). Consistent with previous studies, Casodex enhanced SirT1 abundance at the ARE I-II. DACH1 expression enhanced SirT1 recruitment in the basal state and in the presence of DHT at ARE I-II. DACH1 increased SirT1 recruitment in the presence of Casodex to ARE III. Immunoprecipitation-Western blot analysis detected the increased association of AR with DACH1 in the presence of DHT and recruitment of the corepressor protein HDAC1 and NCoR (Fig. 4C). Mammalian two-hybrid analysis using Gal4-AR and VP16-DACH1 showed their association (Fig. 4D).

DACH1 DS domain–mediated AR repression involves the AR acetylation site. To determine the AR domains required for DACH1-dependent repression, a series of point mutants of the AR were examined in cotransfection experiment. In some patients with prostate cancer, point mutations arise in the carboxyl terminal ligand binding domain and contribute to promiscuous activation of the AR by different ligands. It has been considered that these mutations may thereby contribute to androgen antagonist failure (11). Using the androgen-responsive reporter PSA-luc in DU145 cells, comparison was made with point mutations of the AR acetylation site, as mutation of this site has been identified in prostate cancer and this site is a key determinant of androgen-dependent prostate tumor cellular growth (15, 16). As DACH1 repression of the wt AR was reduced by deletion of the DS domain and the DS domain was sufficient for repression of the wt AR (Fig. 3A), we tested the effect of DACH1 on the AR acetylation site point mutants using the DACH1 DS domain. Point mutation of the
AR acetylation site enhanced ligand-induced transactivation (Fig. 5A) as previously described (15), inducing PSA activity ~ 10-fold. In contrast with AR wt, expression of the DACH1 DS domain failed to repress the gain-of-function AR acetylation point mutant. These studies suggest involvement of the AR acetylation site in AR repression by the DACH1 DS domain. An acetylation site dead mutant (ARK630A) failed to induce AR activity. No significant interaction was observed upon the expression of DACH1 (Fig. 5A).

The role of the AR carboxyl (C)-terminus was next examined. A series of point mutations in the AR COOH terminus were examined for DACH1 repression. The AR wt and ligand-binding domain point mutants each activated PSA activity (Fig. 5B). Ligand-dependent activity was normalized to 100% to enable an assessment of DACH1 repression. DACH1 inhibited ligand-dependent activation of the PSA promoter assessed using either the wt AR or each of the ligand binding domain AR point mutants (Fig. 5B). Collectively, these studies suggest the interaction between DACH1 and the AR does not involve the COOH-terminal ligand binding domain and may involve the AR acetylation site.

**DACH1 repression of AR signaling involves class III deacetylases.** AR activity is determined by coactivators including p300, SRC-1, TIP60, and ARA-70. Reporter gene assays were conducted to examine the effect of these coactivator proteins on DACH1-mediated repression of the AR. Ligand-dependent augmentation of AR activity was induced by p300 and SRC-1, and the expression of p300 and SRC-1 overcame the effect of DACH1 repression on PSA luciferase activity in the presence of DHT in both LNCaP and DU145 cells (Supplementary Fig. S2, lanes 6 versus 8; Fig. 5C and D). Similarly, expression of pCAF, TIP60, or ARA-70 was capable of overcoming DACH1 repression of AR activity in the presence of ligand in both LNCaP and DU145 cells (Supplementary Fig. S2A–E, lanes 6 versus 8). Collectively, these studies show AR coactivators may either partially or completely rescue DACH1-dependent AR repression.

The AR acetylation site gain-of-function mutant ARK630Q evaded repression by the DACH1 DS domain. Endogenous SIRT1, a class III HDAC, constitutively represses AR activity in prostate cancer cells (10, 34, 35). We examined the role of endogenous Sirt1 in DACH1 repression using Sirt1 inhibitors (nicotinamide, Sirtinol, splitomycin). AR activity was assayed using the PSA promoter in HEK293T cells. AR activity was induced ~4.5-fold by DHT and repressed 50% by DACH1. The addition of Nicotinamide (5 mM) reversed the DACH1-dependent repression in the presence of ligand (Fig. 6A). DACH1 repression of DHT-dependent AR activity was not effected by the addition of TSA (Fig. 6B). Coexpression of either HDAC1 or HDAC3 augmented DACH1-dependent repression of the AR responsive PSA promoter (Fig. 6C). In addition to the known association of class I/II HDACs with DACH1, the current studies suggest class III HDACs are involved in DACH1-repression of the AR.

**Discussion**

The current studies show that DACH1 inhibits DHT-dependent AR signaling. DACH1 inhibited DHT-dependent DNA synthesis, cellular proliferation, and contact-dependent growth. DACH1

**Figure 5. DACH1 inhibition of AR reporter gene activity via the AR acetylation site and overcome by p300.** A. Luciferase reporter gene assays were conducted using the AR-responsive PSA-Luc reporter gene. Cells were cotransfected with the AR wt or AR mutants and DACH1 DS domain as indicated. The AR K630 site is acetylated in response to ligand. ARK630Q, a gain-of-function mutant; ARK630A, an acetylation-dead mutant. B. AR wt or carboxyl terminal ligand binding mutants were assessed for DACH1 repression. p300 (C) and SRC-1 (D) enhanced AR activation and overcome DACH1 repression. Columns, mean of five separate transfections; bars, SE.
repression of the AR was dependent on the ARE, the presence of the AR, and the presence of the AR ligand DHT. Repression of AR activity required the conserved DS domain of DACH1. This region of DACH1 is conserved with the Sno/Ski oncogenes. However, neither Ski nor Sno repressed ligand-dependent AR activity. The DS domain alone was sufficient for repression of ligand-dependent AR activity. The DS domain is known to physically associate with NCoR/HDAC1 and HDAC3 (23, 24). ARE activity is determined by the relative abundance of coactivators and corepressor proteins that either encode or recruit HDAC activity. The AR corepressors, including NCoR, SMRT, HDAC1/3, and SIRT1 (8, 9, 19, 36, 37), play a key role in regulating ligand-dependent activity (38). The current studies are consistent with a model in which DACH1 recruits known AR corepressors to maintain the AR in a repressed state.

The DS domain of DACH1 was sufficient for repression of AR activity. Point mutation of the AR within the carboxyl terminus did not affect the magnitude of repression by DACH1. Thus DACH1, like SIRT1 (10, 34), inhibits the activity of mutant AR that arise in patients that are resistant to androgen ablation therapy. Point mutation of the AR acetylation site, however, created an AR mutant that was defective in repression by the DS domain. The AR is modified by phosphorylation, acetylation, ubiquitination, and sumoylation (38). The AR acetylation at lysine residues 630, 632, and 633 is known to enhance AR activity and gain-of-function mutations of the AR acetylation site (AR630Q, AR630T) convey enhanced growth and reduced apoptosis in human prostate cancer cells in culture and in vivo in nude mice (15). Molecular analysis of the gain-of-function AR acetylation site mutants showed enhanced binding of coactivator proteins (p300) and reduced binding of the corepressor complex including NCoR, HDAC1, HDAC3, SMAD6 (15). The finding that the DACH1 DS domain failed to repress the gain-of-function AR acetylation site mutant is consistent with previous studies showing DACH1 binds NCoR, HDAC1/3, SMAD6 (15), and studies showing HDAC1/3 and NCoR (15, 16) have reduced binding affinity to this AR acetylation site mutant.

Herein, the AR was recruited to an ARE in the presence of ligand. In the current studies, DACH1 was recruited to both the proximal promoter (ARE I-II) and the distal enhancer (ARE III) and augmented NCoR recruitment. DACH1 enhanced Casodex-mediated recruitment of NCoR to the distal enhancer ARE III. The mechanisms governing NCoR recruitment are important as transcriptional repression by the AR induced by androgen antagonist is dependent on recruitment of a corepressor complex involving NCoR. Furthermore, NCoR seems to be required for transcriptional repression by androgen antagonists, and Casodex (bicalutamide) may function as an agonist in the absence of this corepressor (35–38). Previous studies have been consistent with a model in which the AR binds to and represses target gene transcription upon binding an androgen antagonist. Antagonist-bound AR undergoes a conformational change, rendering it competent to bind transcriptional corepressors. The current studies show that DACH1 expression is associated with the recruitment of NCoR in the absence of androgen antagonist. DACH1 thus functions to recruit the NCoR corepressor in the absence of antagonist.

The repression of AR activity was dependent on Nicotinamide, adenosine-dinucleotide. The class III HDAC family encoded by the Sirtuin proteins, which regulate diverse biological processes involved in the stress response, metabolism, apoptosis, aging, and nuclear receptor function (22). Sirt1 regulates transcription factors including p53, Foxo proteins, MyoD, nuclear factor-κB, and the
p300 and PGC1α coactivators (22). Consistent with a prior study (34), SirT1 was recruited to ARE I/II upon Casodex treatment. SirT1 inhibits ligand-dependent AR-transactivation (34) and is required for AR antagonist–induced transcriptional repression (34). SirT1 deacetylates and represses AR activity (10). In a previous study, SirT1 was recruited in the context of local chromatin at AREs (10, 34). Herein, DACH1 enhanced SirT1 recruitment to the endogenous ARE of the PSA gene. SirT1 is expressed in prostate cancer and represses AR activity and AR-dependent cellular proliferation (10, 34). DACH1 such as Casodex recruits SirT1. DACH1 loss in prostate cancer may uncouple SirT1 repression. The inactivation of DACH1 repression by the SIRT1 inhibitors (Sirtinol, nicotinamide) are consistent with the participation of class III HDAC in DACH1 function. Thus, DACH1 repression of the liganded AR involves Type I/II and Type III HDAC activity.

The Dachshund gene encodes a protein of the helix-turn-helix family with a winged Forkhead structure (26). Initially described as HDAC in DACH1 function. Thus, DACH1 repression of the liganded proliferation (10, 34). DACH1 such as Casodex recruits SirT1.

endogenous ARE of the
for AR antagonist–induced transcriptional repression (34). SirT1 was recruited to ARE I-II upon Casodex treatment. SirT1

Cancer Research
2009; 69: (8). April 15, 2009 3354 www.aacrjournals.org

References

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Cancer Research
2009; 69: (8). April 15, 2009 3354 www.aacrjournals.org

Downloaded from cancerres.aacrjournals.org on July 22, 2017. © 2009 American Association for Cancer Research.
32. Matsumura I, Kitamura T, Wakao H, et al. Transcrip- 
tional regulation of cyclin D1 promoter by STAT5: its 
involvement in cytokine-dependent growth of hemat- 
PPARγ-mediated adipogenesis through HDAC recruit- 
34. Dai Y, Ngo D, Forman LW, et al. Sirtuin 1 is required 
for antagonist-induced transcriptional repression of 
androgen-responsive genes by the androgen receptor. 
35. Fu M, Wang C, Zhang X, Pestell RG. Nuclear receptor 
modifications and endocrine cell proliferation. J Steroid 
36. Chen JD, Evans RM. A transcriptional co-repressor 
that interacts with nuclear hormone receptors. Nature 
37. Liao G, Chen LY, Zhang A, et al. Regulation of 
androgen receptor activity by the nuclear receptor 
38. Wang L, Hsu CL, Chang C. Androgen receptor 
39. Keisman EL, Baker BS. The Drosophila sex determi- 
nation hierarchy modulates wingless and decapentaple-
gic signaling to deploy dachshund sex-specifically in the 
40. Sanchez L, Gorfrinkel N, Guerrero I. Sex determina-
tion genes control the development of the Drosophila 
genital disc, modulating the response to Hedgehog, 
Wingless and Decapentaplegic signals. Development 
2001;128:1033–43.
The Cell Fate Determination Factor Dachshund Inhibits Androgen Receptor Signaling and Prostate Cancer Cellular Growth

Kongming Wu, Sanjay Katiyar, Agnes Witkiewicz, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-08-3821

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2009/04/06/0008-5472.CAN-08-3821.DC1

Cited articles
This article cites 40 articles, 20 of which you can access for free at:
http://cancerres.aacrjournals.org/content/69/8/3347.full#ref-list-1

Citing articles
This article has been cited by 11 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/69/8/3347.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.